SEC Form 4 · accession 0001209191-17-045998
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
William H Rastetter
Director
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 5:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1,F3 | $6.56 | Jul 19, 2017 | A | 2,000 | A | — | Jul 19, 2027 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017.
- F2Dr. Rastetter was awarded options to purchase shares of the Corporation's common stock in connection with his service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan.
- F3The Director Options will vest in equal annual installments over a three-year period measured from the date of grant, subject to Dr. Rastetter's continued service to the Corporation and will become exercisable in full upon a change of control of the Corporation.